Mounjaro (tirzepatide) carries a potential, rare risk of sudden vision loss linked to a serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). In November 2026, the U.S. Food and Drug Administration (FDA) required all GLP-1 receptor agonist medications—including Mounjaro—to add warnings about this potential risk to their safety labels. [1, 2, 3]
What the Risk Actually Means
- Rarity: NAION is rare, and the overall added risk appears small. A direct cause-and-effect link has not been proven, and people taking GLP-1 drugs for diabetes or obesity often have baseline risk factors for optic nerve issues. [1, 2, 3, 4]
- How NAION Happens: It occurs when blood flow to the front of the optic nerve is reduced or blocked, potentially causing sudden, painless vision loss—usually in one eye—that can be permanent. [1, 2]
Symptoms That Need Urgent Care
- Sudden, painless vision loss in one eye (including upon waking) [1]
- Blurred or hazy central vision, or color changes [1]
Do not stop taking Mounjaro without talking to your prescribing doctor first. For more details on the regulatory update, see coverage from BBC News and The Guardian. [1, 2, 3]